Mohamed N. Sharafeldin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamed N. Sharafeldin has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Hamsa Hassan
Medical Research Platform, Giza, Egypt
2 shared publications - Nouran Ahmed Taha
MARS-Global, London, UK
2 shared publications - Achouak Boutalbi1 shared publication
- Ahmed Saeed Yahya
OTC kuwait, Nephrology, Ff, Kuwait
1 shared publication - Amgad El-Said Salem
Mansoura Univ, Fac Pharm, Dept Pharmaceut, Mansoura 35516, Egypt
1 shared publication Amira Ayman Ahmed
Faculty of Science, Cairo University, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 29 October 2025
- Published by Springer Nature in Discover Nano
- Vol. 20 (1) , 1-24
Nano-antioxidants for neurodegenerative disorders: a scoping review
Antioxidants showed usefulness in treating or preventing neurodegenerative diseases (NDDs). However, antioxidants have limited bioavailability owing to the
- 29 October 2025
- Published by Springer Nature in Discover Nano
- Vol. 20 (1) , 1-24
Open AccessNano-antioxidants for neurodegenerative disorders: a scoping review
Antioxidants showed usefulness in treating or preventing neurodegenerative diseases (NDDs). However, antioxidants have limited bioavailability owing to the
- 13 August 2024
- Published by Taylor & Francis
- p. 173-207
Lipid-Based Nanocarriers for Brain Delivery of Bioactives in the Treatment of Neurodegenerative Disorders
Neurodegenerative diseases include diverse conditions (e.g., Parkinson’s disease and Alzheimer’s disease) in which ongoing loss of neurons and glial cells is implicated. They lead to impaired motor and cognitive functions. Although there is an advancement in therapeutic options impacting the pathogenetic mechanisms of the disease, the BBB exerts a physiological barrier that hinders their access to the brain. Thereby, novel drug delivery approaches have been considered to enhance CNS targeting and bioavailability. There is increasing evidence that lipid-based nanocarriers (e.g., liposomes) may improve brain targeting and ease BBB transportation. Nevertheless, no authorized nanoformula targets the CNS till now. We aim to summarize the relevant literature about the different types of lipid-based nanocarriers and the findings of the preclinical and clinical trials conducted so far through systematic and manual searches in PubMed. Hence, it may be inspiring to translate this approach into clinical practice and benefit from their pharmacokinetic characteristics. Moreover, we attempt to highlight the challenges and future outlooks for their implementation in clinical practice. Overall, it is still early for these applications to be translated into clinical practice due to several reasons, including safety concerns; the lack of simple formulas that can be eligible and allow affordable, large-scale production; and the absence of reliable, high-quality, and strong evidence. We suggest that there is a necessity for appropriately designed controlled trials and standardized analytical methods.
- 13 August 2024
- Published by Taylor & Francis
- p. 173-207
Lipid-Based Nanocarriers for Brain Delivery of Bioactives in the Treatment of Neurodegenerative Disorders
Neurodegenerative diseases include diverse conditions (e.g., Parkinson’s disease and Alzheimer’s disease) in which ongoing loss of neurons and glial cells is implicated. They lead to impaired motor and cognitive functions. Although there is an advancement in therapeutic options impacting the pathogenetic mechanisms of the disease, the BBB exerts a physiological barrier that hinders their access to the brain. Thereby, novel drug delivery approaches have been considered to enhance CNS targeting and bioavailability. There is increasing evidence that lipid-based nanocarriers (e.g., liposomes) may improve brain targeting and ease BBB transportation. Nevertheless, no authorized nanoformula targets the CNS till now. We aim to summarize the relevant literature about the different types of lipid-based nanocarriers and the findings of the preclinical and clinical trials conducted so far through systematic and manual searches in PubMed. Hence, it may be inspiring to translate this approach into clinical practice and benefit from their pharmacokinetic characteristics. Moreover, we attempt to highlight the challenges and future outlooks for their implementation in clinical practice. Overall, it is still early for these applications to be translated into clinical practice due to several reasons, including safety concerns; the lack of simple formulas that can be eligible and allow affordable, large-scale production; and the absence of reliable, high-quality, and strong evidence. We suggest that there is a necessity for appropriately designed controlled trials and standardized analytical methods.